Find the right doctor.Get information about our new institute structure.my health. MyChart.Find the right doctor.

Ernest Borden, M.D.

Print this Content
Email this Content
Appointed: 1998
Gender: Male
Languages: English
Translational Hematology and Oncology Research
Phone:(216) 444-8183
Location:Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
Solid Tumor Oncology
Phone:(216) 444-8183
Location:Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
Cancer Biology
Phone:(216) 444-8183
Location:Cleveland Clinic Main Campus
Mail Code R40
9500 Euclid Avenue
Cleveland, OH 44195
 
 
Biographical Sketch

Ernest C. Borden, MD, is the Director of the  Center for Hematology and Oncology Molecular Therapeutics (CHOMT) at Cleveland Clinic and Deputy Director of the Taussig Cancer Institute.   
 
He graduated from Harvard University with an A.B. in biochemistry in 1961. He attended medical school at Duke University School of Medicine, Durham, N.C., and completed his internship at Duke University Medical Center, Durham, N.C.

Dr. Borden also received a fellowship from Johns Hopkins Hospital, Baltimore, Md., and completed his residency at Hospital of the University of Pennsylvania,  Philadelphia, Penn.

His specialty interests include melanoma, sarcomas, new cancer therapies including interferons, vaccines and antibodies.

Back to Top
Professional Highlights
  • Milstein Award, International Society for Interferon Research
  • Smalley Award, International Society of Biological Therapy
  • America's Top Doctors for Cancer
  • Best Doctors in America
Back to Top
Education & Fellowships
Medical School:Duke University School of Medicine, Durham, NC
 
Internship:Duke University Medical Center, Internal Medicine, Durham, NC
Residency:Hospital of University of Pennsylvania, Internal Medicine, Philadelphia, PA
Fellowship:Johns Hopkins Hospital, Medical Oncology, Baltimore, MD
Other Education:(Undergraduate) Harvard University, Cambridge, MA
Back to Top
Certifications

Medical Oncology

Internal Medicine

Back to Top
Specialty Interests
Melanoma, new cancer therapies including interferons, vaccines and antibodies.
Back to Top
Innovations & Patents
  • Method of Reducing the Level of Low Density Lipoproteins in the Serum of a Patient, Ernest C. Borden and Earl Shrago, June 12, 1984, U.S. Patent #4,454,115
  • Activation of Monocytes/Macrophages by a 15Kda Protein.  Ernest C. Borden, et al., July 6, 1999, U.S.
    Patent #5919700
  • Production of IFN Using DA15 Peptide, Ernest C. Borden, et al., May 23, 1995, U.S. Patent #5,418,192
    Method of Proliferating NK/LAK Cells,  Ernest C. Borden, Jon D’Cunha, July 6, 1999, U. S. Patent #5,919,700
Back to Top
Awards & Honors
  • Colonial Dames of America Scholarship, Harvard University, 1957-1961
  • Manoocherian Foundation Scholarship, Duke University Medical School, 1962-1964   
  • Davision Scholar, Oxford University, 1966
  • Junior Faculty Fellow, American Cancer Society, 1975-1978 
  • Wisconsin State Medical Society, Elvehjem Memorial Lecture, 1983
  • Who's Who in Frontier Science and Technology, 1984
  • Award of Merit, Eastern Cooperative Oncology Group, 1984
  • American Cancer Society Professor of Clinical Oncology, 1984-1994  
  • American Men and Women of Science, 1985
  • Who's Who in America, 1986
  • South African Society of Medical Oncology Gold Medal Award, 1987
  • Singapore Malaysia Academy of Medicine Silver Medal, 1990
  • The Best Doctors in America, 1991, 1992, 1993, 1996, 2002, 2004-2008
  • American Cancer Society National Distinguished Service Award, 1994
  • American Cancer Society, Baltimore County, Unit Premier Award, 1995
  • Milstein Award   International Society of Interferon and Cytokine Research 2005
  • Richard V Smalley Award   International Society of Biological Therapy 2007
Back to Top
Professional Memberships
  • American Association for Advancement of Science
  • American Association of Cancer Research
  • American Society of Clinical Oncology
  • International Society of Interferon Research
  • American Society of Hematology
Back to Top
Specializes in Diseases and Conditions
Back to Top
Specializes in Services
Back to Top
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 8/6/2008, Dr. Borden has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting.  Dr. Borden receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
  • Cleveland BioLabs, Inc.
  • EpiCept Corporation

Equity.  Dr. Borden owns stock or stock options in the following companies for activities as a founder, inventor, or consultant:
  • Alios BioPharma, Inc.
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)